Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial

IMPORTANCE: Prior studies have shown that only a small proportion of patients with hormone receptor (HR)–positive metastatic breast cancer (MBC) experience benefit from programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors given as monotherapy. There are data suggesting th...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:JAMA Oncol
Main Authors: Tolaney, Sara M., Barroso-Sousa, Romualdo, Keenan, Tanya, Li, Tianyu, Trippa, Lorenzo, Vaz-Luis, Ines, Wulf, Gerburg, Spring, Laura, Sinclair, Natalie Faye, Andrews, Chelsea, Pittenger, Jessica, Richardson, Edward T., Dillon, Deborah, Lin, Nancy U., Overmoyer, Beth, Partridge, Ann H., Van Allen, Eliezer, Mittendorf, Elizabeth A., Winer, Eric P., Krop, Ian E.
Format: Artigo
Sprog:Inglês
Udgivet: American Medical Association 2020
Fag:
Original Investigation
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7489368/
https://ncbi.nlm.nih.gov/pubmed/32880602
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2020.3524
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker